Medi Caps share price
NSE: MEDICAPQBSE: 523144Pharmaceuticals & BiotechnologySmall Cap
Last close ₹24.95down ₹0.05 (0.20%)BSE ₹25.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹25.00.
52-week range of BSE trades to 23 Oct 2026
₹21.00Low, 11 Mar 2026₹44.70High, 29 Oct 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹31 Cr3,735th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 0.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- −1.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- −8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,595
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2.79 Crdown 19.21%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹2.23 CrQuarter to Mar 2026: ₹3.04 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −80.1%
Revenue by year
Peak revenue ₹70 Cr, year to Mar 2022
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 5 Aug | Sep 2025Filed 12 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 21 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.30 | 4.02 | 6.96 | 2.69 | 2.01 | 4.30 | 3.45 | 2.79 |
| Net profit | 0.31 | −2.05 | 1.72 | −3.49 | −1.82 | −0.77 | 3.04 | −2.23 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 3.8% | −50.8% | 24.7% | −129.9% | −90.5% | −17.8% | 88.2% | −80.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Pharma DevisionPharma Devision, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹10.1 Crdown 56.02%81.5%
- Real Estate DevisionReal Estate Devision, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹2.3 Crdown 4.58%18.5%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 18% of 1,932 trading days since Nov 2018.
LowestHighest
Its median0.4Industry median2.9
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −44.1% | – | – | 0.0% |
| 3 years | −12.8% | – | – | 0.0% |
| 5 years | −10.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Medi Caps in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Medi Caps is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Rajnish WellnessRAJNISH | 35 | – | 0.3 | – | +356.9% | – | – | −8.2% | 0.00% |
 Roopa IndustriesROOPAIND | 34 | 269.3 | 2.0 | 7.7 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Jfl Life SciencesJFLLIFE | 34 | 5.0 | 0.7 | 4.6 | – | – | 15.9% | 15.9% | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 33 | 18.5 | 0.8 | 8.8 | +4.2% | +10.3% | 4.1% | 5.3% | 2.94% |
 Chandra Bhagat PharmaCBPL | 29 | 10.4 | 0.9 | – | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.0 | 2.0 | – | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 7.0 | – | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 29 | – | 1.1 | – | – | – | – | −0.7% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
| Ex-date | Type | Per share |
|---|---|---|
| 20 Sep 2012 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 22 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 22 Sep 2010 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 24 Sep 2009 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 24 Sep 2008 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 20 Sep 2007 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
23 Sep · Announcements Under Regulation 30(LODR)
Aug 2026
25 Aug · Intimation For Dispatch Of Letter To Those Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent/Depository Participants
Medi Caps share price by year
Each calendar year to 2025.Medi Caps share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 31.23 | −35.9% | 57.90 | 30.28 |
| 2024BSE close | 48.75 | −0.6% | 60.03 | 43.93 |
| 2023BSE close | 49.04 | +7.8% | 52.04 | 32.04 |
| 2022BSE close | 45.50 | −5.1% | 86.35 | 42.85 |
| 2021BSE close | 47.95 | +104.9% | 51.50 | 21.85 |
| 2020BSE close | 23.40 | +103.3% | 25.55 | 7.48 |
| 2019BSE close | 11.51 | −15.6% | 19.75 | 10.90 |
| 2018BSE close | 13.64 | −54.5% | 35.95 | 13.37 |
| 2017BSE close | 29.95 | +31.1% | 32.10 | 21.30 |
| 2016BSE close | 22.85 | −32.2% | 34.85 | 17.55 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 23.80 | 26.25 | 23.75 | 24.95 | 23.98 | 1,595 |
| 22 Oct 2026 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 3 |
| 21 Oct 2026 | 26.25 | 26.25 | 24.00 | 25.50 | 25.48 | 1,007 |
| 19 Oct 2026 | 26.10 | 26.10 | 25.00 | 25.00 | 25.09 | 940 |
| 16 Oct 2026 | 25.99 | 25.99 | 25.00 | 25.84 | 25.35 | 309 |
| 15 Oct 2026 | 25.99 | 25.99 | 24.75 | 25.00 | 24.98 | 328 |
| 14 Oct 2026 | 26.07 | 26.07 | 25.00 | 25.97 | 25.10 | 1,001 |
| 13 Oct 2026 | 26.20 | 26.25 | 23.81 | 26.07 | 24.01 | 474 |
| 12 Oct 2026 | 25.00 | 25.00 | 24.50 | 25.00 | 24.94 | 130 |
| 9 Oct 2026 | 25.50 | 25.50 | 25.50 | 25.50 | 25.50 | 1,292 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Mar 2013 | Bonus | 0.2500 | Holders received 3 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Medi Caps Limited
- NSE symbol
- MEDICAPQ
- BSE code
- 523144
- ISIN
- INE442D01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1987
- Face value
- ₹10
- CIN
- L70100MP1983PLC002231
- Corporate identity number, the registrar of companies' code for it